Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical surveillance versus rivaroxaban anticoagulation for low-risk isolated subsegmental pulmonary embolism
2020-000353-26Phase 4Active
- Sponsor
- Inselspital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of rivaroxaban in pulmonary embolism (PE) (2 arms), sponsored by Inselspital. Primary endpoint: Primary efficacy endpoint. Started Apr 2021; status: active.
02
Drugs
rivaroxaban
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on 2020-000353-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000353-26.